European Conference on Interventional Oncology
Interventional Oncology 2.0
Interventional Oncology 2.0
Interventional Oncology 2.0
ProgrammeECIO Virtual

ECIO Virtual

ECIO Virtual is a new initiative by CIRSE to provide interventional oncologists from around the world with the latest information and education in the exciting and fast-growing field of interventional oncology. This series of 4 afternoon webinars will take place between November 2020 and February 2021, each of them starting at 15:00 CET and comprising up to 4 live sessions as well as exclusive purpose-made on-demand content.

Each of the four instalments of ECIO Virtual has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 3 European CME credits (ECMEC®s). Find out more!

Colorectal cancer and cholangiocarcinoma

We caught up with ECIO SPC Chairperson Prof. Alban Denys to find out what to look forward to in the second instalment of the ECIO Virtual webinar series.

Hepatocellular carcinoma

15:00-16:30 CET
Hepatocarcinoma: from classification to treatment

Moderators: L. Crocetti (Pisa/IT), M. Fuchs (Munich/DE)

  • Critical view on HCC classification | M. Ronot (Clichy/FR)
  • Borderline in HCC nodules: the early stage | P.L. Pereira (Heilbronn/DE)
  • Borderline in HCC nodules: the intermediate stage | I. Bargellini (Pisa/IT)
  • Trials vs. reality: what is the role of radioembolisation? | E. Garin (Rennes/FR)
  • HCC and systemic treatment in 2020 | A. Vogel (Hannover/DE)
  • Q&A and discussion

16:30-17:00 CET
Satellite Symposium

17:30-18:00 CET
Highlighted free papers

18:00-19:30 CET
HCC: patient management

Moderators: R. Lencioni (Pisa/IT), K. Malagari (Athens/GR)

  • Current status of biopsy in HCC | J. Bell (Manchester/UK)
  • The bleeding HCC tumour: management and outcomes | M. Burrel (Barcelona/ES)
  • HCC with portal vein invasion | R. Salem (Chicago/Il, US)
  • HCC in non-cirrhotic liver | H. Pinto Marques (Lisbon/PT)
  • Combining locoregional treatment and immunotherapy in 2020 | P. Reimer (Karlsruhe/DE)
  • Q&A and discussion

On-demand sessions made available

Cancer immunotherapy: clinical results

  • Resistance to systemic immunotherapy: how to overcome | J. Haanen (Amsterdam/NL)
  • Immunotherapy in 2020: clinical indications | G. Curigliano (Milan/IT)
  • Checkpoint inhibitors in HCC, lung and renal tumours | U. Martens (Heilbronn/DE)
  • Beyond checkpoint inhibitors | V. Gambardella (Valencia/ES)
  • Pseudo- and hyperprogression: clinical impact | S.Champiat (Villejuif/FR)

Upcoming European research

  • Intratumoral immunotherapy | L.Tselikas (Villejuif/FR)
  • Cryo priming in immunoresponse | R.Duran (Lausanne/CH)
  • Combining IRE and immunotherapy | H.J. Scheffer (Amsterdam/NL)
  • Serum and tumoral biomarkers can predict recurrence after HCC locoregional therapies | R. Muglia (Rozzano/IT)
  • Direction of travel for IO research | N. Goldberg (Jerusalem/IL)

Free Paper and poster presentations

Colorectal cancer and cholangiocarcinoma

15:00-16:30 CET
Metastatic colorectal cancer

Moderators: D. Arnold (Hamburg/DE), P.L. Pereira (Heilbronn/DE)

  • Patient selection for locoregional treatment on a molecular basis | C. Sofocleous (New York/NY, US)
  • Patient selection for locoregional treatment: clinical selection | D. Arnold (Hamburg/DE)
  • Update on ablation results in colorectal liver mets | M.R. Meijerink (Amsterdamn/NL)
  • Combined approach to extend curative treatment | A. Denys (Lausanne/CH)
  • Intra-arterial therapies: where are we now? | F. Orsi (Milan/IT)
  • Lung mets metastases local treatment | T. de Baère (Villejuif/FR)
  • Q&A and discussion

18:00-19:30 CET

Moderators: P.L. Pereira (Heilbronn/DE), T.K. Helmberger (Munich/DE)

  • Imaging of perihilar carcinoma | C.J. Zech (Basel/CH)
  • Perihilar cholangiocarcinoma: staging and surgical results | G. Kazemier (Amsterdam/NL)
  • Endobiliary treatments of PCC: from light to waves | V. Válek (Brno/CZ)
  • Percutaneous ablative treatments of PCC and mass forming cholangiocarcinoma | K.P. van Lienden (Amstedam/NL)
  • Intra-arterial treatments for cholangiocarcinoma | F. Wacker (Hannover/DE)
  • Q&A and discussion

On-demand sessions made available

Image guidance: case-based discussion

  • How to enhance conspicuity for hardly visible tumours | F. Deschamps (Villejuif/FR)
  • How to confirm the ablation is complete | F.T. Lee (Madison/WI, US)
  • Combined CT and angio systems over CBCT: pro | B. Guiu (Montpellier/FR)
  • Combined CT and angio systems over CBCT: con | M. van Strijen (Nieuwegein/NL)
  • Tumour feeder detection: software solutions and clinical results | H. Kobeiter (Creteil/FR)
  • Does guidance improve results? | R. Bale (Innsbruck/AT)

Interventional oncology to optimise liver surgery

  • Liver failure after surgery: definition and risk factors | A. Iannelli (Nice/FR)
  • How to better predict liver function: MR with primovist, CT volumetry, and Mebrofenin scintigraphy | M. Ronot (Clichy/FR)
  • ALPPS: a critical review | E. Melloul (Lausanne/CH)
  • Radioembolisation is the best way to promote liver growth | R. Salem (Chicago/IL, US)
  • Portal vein embolisation: technical issues | J.H. Luz (Lisbon/PT
  • PVE: liver venous deprivation | B. Guiu (Montpellier/FR)


  • Local delivery of immunotherapy: drugs candidates | S. Champiat (Villejuif/FR)
  • Local delivery of immunotherapy: routes | T. de Baère (Villejuif/FR)
  • Local delivery of immunotherapy: results | J. Brody (New York/NY, US)
  • Ablation and immunomodulation: the best scheme and technique | S. Haen (Tübingen/DE)
  • Intra-arterial treatments and immunomodulation: the best scheme and technique | R. Duran (Lausanne/CH)
  • Combining IO treatment and systemic immunotherapy: clinical results | A. Digklia (Lausanne/CH)

Lung and renal tumours

15:00-16:30 CET
Primary lung tumours

Moderators: T. de Baère (Villejuif/FR), J. Palussière (Bordeaux/FR), T.J.Kroencke (Augsburg/DE)

  • Biopsies of lung tumours | J.-Y. Gaubert (Marseille/FR)
  • Stage I surgery: sub lobar, VATS, robotics and results | C. Wimmer (Heidelberg/DE)
  • Early-stage tumours: indications & limitations of SBRT | S. Heymann (Strasbourg/FR)
  • Early-stage tumours: results of thermal ablation | R.D. Suh (Los Angeles/CA, US)
  • Oligometastatic lung cancer: optimal management | C. Sofocleous (New York/NY, US)
  • New concepts in lung cancer | C. Ottensmeier (Southampton/UK)
  • Q&A and discussion

16:30-17:00 CET
Satellite Symposium

17:30-18:00 CET
Satellite Symposium

18:00-19:30 CET
Renal cancer ablation: moving forward

Moderators: D. Breen (Southampton/UK), A. Bex (Amsterdam/NL)

  • T1 renal disease: scope of the problem | E. de Kerviler
  • How to manage renal cancer syndromes | E. Woodward
  • Ablation and surgery: functional impact? | O.Graumann
  • Surgery for T1 renal tumours: current trends | A. Bex
  • Optimising renal tumour ablation | D. Breen
  • Renal tumour ablation: avoiding complications | G. Schmit
  • Q&A and discussion

On-demand sessions made available

Imaging and clinical follow-up

  • Liver ablation | L. Crocetti (Pisa/IT)
  • Liver chemoembolisation | E. Coimbra (Lisbon/PT)
  • Liver radioembolisation | I. Bargellini (Pisa/IT)
  • Kidney ablation | J.-M. Correas (Paris/FR)
  • Lung ablation and SBRT | R. Suh (Los Angeles/CA, US)
  • Pancreas ablation | N. Beydoun (Poitiers/FR)

Nuclear medicine and interventional oncology – present and future

  • New targets in nuclear medicine opportunities for IO | N. Schaefer (Lausanne/CH)
  • Intra-arterial PRRT liver metastases from NET | M. Mustafa (Munich/DE)
  • Kidney and lung radioembolisation | J. Ricke (Munich/DE)
  • PET PSMA and prostate cancer | C. la Fourère (Tübingen/DE)
  • Yttrium, Holmium, Radium, etc. | M.G.E.H. Lam (Utrecht/NL)
  • Lipiodol in nuclear medicine is back | E. Garin (Rennes/FR)

Palliation in oncology

  • Abdominal neurolysis: optimising results | D.K. Filippiadis (Athens/GR)
  • Improving nutrition in cancer patients | H.-U. Laasch (Manchester/UK)
  • Ascites in cancer patients | G. Narayanan (Miami/FL, US)
  • Bleeding complications after radiotherapy: how to manage | L. Tselikas (Villejuif/FR)
  • Palliation of carcinoid syndrome | J. Urbano (Madrid/ES)
  • Vascular complications after Whipple procedure | D. Poretti (Rozzano/IT)

Tips and tricks: case-based discussion

  • Lymphatic leaks | P. Rao (Colmar/FR)
  • Combined TACE and ablation | T. Jakobs (Munich/DE)
  • Nerve protection in the pelvis | A.N. Kurup (Rochester/MN, US)
  • Liver: complex biliary procedures | D.W. de Boo (New Lambton Heights/AU)
  • Portal vein occlusion after abdominal surgery | J. Bell (Manchester/UK)
  • Extrahepatic feeders for TACE | S.J. Park (Icheon/KR)

Musculoskeletal – curative and palliation therapies

15:00-16:30 CET
MSK: curative treatment in oligometastatic bone disease

Moderators: A. Gangi (Strasbourg/FR) M. Callstrom (Rochester/MN, US)

  • Who is the ideal candidate for local treatment? | M. Callstrom (Rochsester/MN, US)
  • SBRT – results for complete local remission | S. Heymann (Strasbourg/FR)
  • Ablation tools and how to use them | J. Jennings (St. Louis/MO, US)
  • Avoiding complications: tips and tricks | R. Cazzato (Strasbourg/FR)
  • Results of ablation | R.-T. Hoffmann (Dresden/DE)
  • Challenges in imaging follow-up: ablation vs. SBRT | A. Kelekis (Athens/GR)
  • Round table discussion | Panel

16:30-17:00 CET
Satellite Symposium

17:30-18:00 CET
Satellite Symposium

18:00-19:30 CET
MSK palliation: the pelvic bone

Moderators: J. Jennings (St. Louis/MO, US), A. Kelekis (Athens/GR)

  • Biomechanics and anatomy of the pelvic bone | J. Garnon (Strasbourg/FR)
  • Clinical and radiological evaluation | S. Bauones (Montreal/QC, CA)
  • Surgery: what is feasible and what is reasonable? | M. Jayankura (Brussels/BE)
  • Percutaneous cementoplasty | A. Kurup (Rochester/MN, US)
  • Percutaneous screw fixation | F. Deschampes (Villejuif/FR)
  • When and how to ablate | D. Filippiadis (Athens/GR)
  • Q&A and discussion

On-demand sessions made available

Challenges in interventional oncology

  • IO in pediatrics | A.M. Barnacle (London/UK)
  • Chemosaturation and liver tumours | S. Modi (Southhampton/UK)
  • Central liver tumours: we don’t need IRE | P. Chevallier (Nice/FR)
  • Central liver tumours: IRE is the solution | O. Seror (Bondy/FR)
  • Starting an MR-guided programme | A. King (Southampton/UK)
  • Brain tumours: IO solutions | G. Gahide (Montreal/QC, CA)

Other organs ablation

  • Adrenal | R.L. Cazzato (Strasbourg/FR)
  • Breast: local | J. Palussière (Bordeaux/FR)
  • Pancreas: local | H.J. Scheffer (Amsterdam/NL)
  • Lymph nodes | G. Tsoumakido (Lausanne/CH)
  • Thyroid cancer | R. Cervelli (Pisa/IT)
  • Soft tissue tumour | T.K. Helmberger (Munich/DE)

Robotics and AI

  • Artificial intelligence in oncology | F. Gleeson (Oxford/UK)
  • Artificial intelligence in interventional oncology | J. Chapiro (New Haven/CT, US)
  • Treatment planification | A. King (Southhampton/UK)
  • Robotics for ablation | K. de Jong (Groningen/NL)
  • Robotics, AI,…where is the future heading? | B.J. Wood (Bethesda/MD, US)

Video learning session – How I do it

  • Hepatic intra-arterial port | Y. Arai (Tokyo/JP)
  • MR-guided prostate interventions | J.J. Fütterer (Nijmegen/NL)
  • Organ protection and ablation | R. Iezzi (Rome/IT)
  • Liver venous deprivation: transjugular approach | M. Vermersche (Lille/FR)
  • Chemosaturation | G.M.Varano (Milan/IT)
  • Pancreatic IRE | G. Narayanan (Miami/FL, US)

Be part of it!

Registration for the ECIO Virtual webinar series will be available shortly. CIRSE members will be able to register free of charge. Non-members will be able to acquire access to the entire webinar series for €95.